ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pleased to speak with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked about the long-term PFS outcomes with ciltacabtagene autoleucel (cilta-cel) for standard-risk relapsed/refractory multiple myeloma (RRMM) from the from the CARTITUDE-4 trial.

In this interview, Costa first provided an overview of the phase III CARTITUDE-4 (NCT04181827) study design, explaining how the findings have impacted the treatment landscape for multiple myeloma. He then discussed the subgroup of patients in the trial with standard-risk cytogenetics, highlighting the high proportion who remain progression-free 30 months after receiving cilta-cel. He concluded by considering the potential impact of these findings and the possibility that cilta-cel may offer a single-dose curative option for these patients.

Key points

• The phase III, randomized CARTITUDE-4 trial included patients with lenalidomide-refractory multiple myeloma who had received 1–3 prior lines of therapy.
• Patients with standard-risk cytogenetics who received cilta-cel (as-treated population) had a 30-month PFS rate of 80.5% (71.1% including patients with gain/amplification of chromosome arm 1q [+1]) vs 59.9% in those treated with standard-of-care (including +1q).
  • 93% of patients who were progression free at 1 year remained alive and progression-free at 30 months.
• All patients who were measurable residual disease (MRD)-negative 12 months after receiving cilta-cel (81% of the MRD-evaluable population) were progression-free at 30 months.
• The PFS rate was higher than that seen in CARTITUDE-1, which assessed cilta-cel in patients with RRMM who had received ≥3 prior lines of therapy, suggesting cilta-cel may be beneficial as an earlier treatment option.

This educational resource is independently supported by Legend Biotech. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.